ALCON RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effects of Travatan Z and Xalatan on Ocular Surface Health

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)

First Posted Date: 2008-07-02

Last Posted Date: 2012-04-23

Lead Sponsor: Alcon Research

Target Recruit Count: 231

Registration Number: NCT00708422

A Multi-Dose Study With a Treatment for Open-Angle Glaucoma

Phase 2

Withdrawn

Conditions: Open-Angle Glaucoma

Interventions: Drug: Placebo
Drug: Anecortave Acetate

First Posted Date: 2008-06-26

Last Posted Date: 2012-05-30

Lead Sponsor: Alcon Research

Registration Number: NCT00705770

Evaluation of SYSTANE Ultra Lubricant Eye Drops

Not Applicable

Completed

Conditions: Dry Eye

Interventions: Other: SYSTANE Ultra
Other: Optive

First Posted Date: 2008-06-20

Last Posted Date: 2012-02-02

Lead Sponsor: Alcon Research

Target Recruit Count: 109

Registration Number: NCT00702377

Locations: 🇺🇸
Contact Call Center for Locations, Fort Worth, Texas, United States

Tobramycin Tear Concentrations

Phase 1

Completed

Conditions: Dry Eye

Interventions: Drug: TOBREX Ophthalmic Solution
Drug: TOBRADEX Ophthalmic Suspension
Drug: Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension

First Posted Date: 2008-06-11

Last Posted Date: 2010-03-02

Lead Sponsor: Alcon Research

Target Recruit Count: 21

Registration Number: NCT00695435

Locations: 🇺🇸
Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States

Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)

First Posted Date: 2008-06-05

Last Posted Date: 2012-07-24

Lead Sponsor: Alcon Research

Target Recruit Count: 726

Registration Number: NCT00690794

Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)

Completed

Conditions: Open-Angle Glaucoma

Interventions: Other: Blood Collection Only

First Posted Date: 2008-06-05

Last Posted Date: 2009-10-01

Lead Sponsor: Alcon Research

Target Recruit Count: 1000

Registration Number: NCT00691639

Locations: 🇺🇸
Alcon Call Center, Fort Worth, Texas, United States

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Open-angle Glaucoma
Oular Hypertension

Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 75 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2008-06-05

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 201

Registration Number: NCT00691717

Locations: 🇺🇸
Charleston, Charleston, South Carolina, United States

Comparison of 3 Novel Contact Lens Solutions on the Basal Lamina

Not Applicable

Completed

Conditions: Contact Lens Solution

Interventions: Device: Opti-Free contact lens solution
Device: ReNu Multiplus contact lens solution
Device: Clear Care contact lens solution

First Posted Date: 2008-06-05

Last Posted Date: 2012-10-01

Lead Sponsor: Alcon Research

Target Recruit Count: 15

Registration Number: NCT00691457

Locations: 🇺🇸
Virginia Beach, VA, Virginia Beach, Virginia, United States

Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial

Phase 4

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Olopatadine HCL Nasal Spray, 0.6%
Drug: Fluticasone Propionate Nasal Spray, 50 mcg

First Posted Date: 2008-06-05

Last Posted Date: 2010-03-30

Lead Sponsor: Alcon Research

Target Recruit Count: 130

Registration Number: NCT00691665

Locations: 🇺🇸
Sacramento, CA, Sacramento, California, United States

ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)

Phase 4

Completed

Conditions: Cataract

Interventions: Device: ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
Device: ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens

First Posted Date: 2008-05-26

Last Posted Date: 2010-07-13

Lead Sponsor: Alcon Research

Target Recruit Count: 300

Registration Number: NCT00684138

Locations: 🇺🇸
Call Center for Locations, Fort Worth, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy